Join
Live feed
·
PRReleasevia Quantisnow
Abivax SA logo

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

ByQuantisnow·Wall Street's wire, on your screen.
ABVX· Abivax SA
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABVX (Abivax SA) and more on Quantisnow.